Day One (DAWN) Q2 Revenue Jumps 313%

Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company focused on developing therapies for pediatric cancers and rare tumor types, reported its earnings for Q2 2025 on August 5, 2025. The main headline: robust growth in OJEMDA (tovorafenib) prescription numbers and revenue, although total quarterly revenue (GAAP) of $33.9 million came in slightly below the analyst consensus of $34.9 million. Earnings per share (GAAP) matched the analyst forecast at a loss of $0.36. The period saw strong execution in commercial rollout and cost discipline, setting up for what management expects to be continued growth for the year. Source: Analyst estimates for the quarter provided by FactSet. Day One Biopharmaceuticals develops targeted therapies for children and adults with rare cancers, focusing on high unmet medical needs. Its core product, OJEMDA, is an oral inhibitor that targets specific genetic alterations commonly found in pediatric low-grade glioma, a type of brain tumor in children. The company's approach involves licensing, developing, and commercializing innovative oncology drugs with the help of partnerships such as those with Ipsen for non-U.S. markets and MabCare for pipeline expansion.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool